Persephone Biosciences Closes $15M Seed Financing Round
Summary
SAN DIEGO--(BUSINESS WIRE)--Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Societys BrightEdge Fund, Pioneer Fund, and ZhenFund among others.This financing is a significant milestone for Persephone and the culmination of years of thoughtful engagement with forward-thinking investors and individuals who are committed to the vast potential of our platform and technology, said Stephanie Culler, CEO and Co-founder of Persephone Biosciences. We are grateful for the support of all our stakeholders and their commitment and confidence in our vision.Persephone was founded to leverage a unique understanding of the microbiome as a therapeutic approach for a number of indications, including infant health and oncology. The companys ARGONAUT trial (NCT04638751) is the largest study ever conducted in the U.S. to identify biomarkers for cancer treatment and prevention by mapping the gut-immune axis. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler, Ph.D., and Steve Van Dien, Ph.D. For more information, visit us at persephonebiosciences.com and follow us on Twitter and LinkedIn.